Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

被引：0

作者：

Von Minckwitz, Gunter

Hahnen, Eric

Fasching, Peter A.

Hauke, Jan

Schneeweiss, Andreas

Salat, Christoph

Rezai, Mandi

Blohmer, Jens U.

Zahm, Dirk Michael

Jackisch, Christian

Gerber, Bernd

Klare, Peter

Kummel, Sherko

Eidtmann, Holger

Paepke, Stefan

Nekljudova, Valentina

Le Loibl, Sibyl

Untch, Michael

Schmutzler, Rita K.

机构：

[1] Goethe Univ Frankfurt, German Breast Grp, D-60054 Frankfurt, Germany

[2] Univ Cologne, D-50931 Cologne, Germany

[3] Univ Erlangen Nurnberg, Dept Obstet & Gynecol, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, D-91054 Erlangen, Germany

[4] Univ Heidelberg Hosp, Heidelberg, Germany

[5] Hematol Oncol Clin, Munich, Germany

[6] Louisen Hosp, Breast Ctr Duesseldorf, Dusseldorf, Germany

[7] Brustzentrum Sankt Gertrauden Krankenhaus, Berlin, Germany

[8] Frauenklin Gera, Gera, Germany

[9] Sana Kliniken Offenbach, Offenbach, Germany

[10] Univ Rostock, D-18055 Rostock, Germany

[11] Praxisklin Krebsheilkunde, Berlin, Germany

[12] Evangel Huyssens Stiftung, Kliniken Essen Mitte, Breast Canc Ctr, Essen, Germany

[13] Univ Kiel, Kiel, Germany

[14] Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-80290 Munich, Germany

[15] German Breast Grp, Neu Isenburg, Germany

[16] Sana Klinikurn Offenbach, German Breast Grp, Neu Isenburg, Germany

[17] Helios Klinikum Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany

[18] Helios Klinikum Berlin Buch, Multidisciplinary Breast Canc Ctr, Berlin, Germany

[19] Ctr Familial Breast & Ovarian Canc, Cologne, Germany

[20] Ctr Integrated Oncol, Cologne, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1005

引用

页数：1

共 50 条

[1] Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.
Von Minckwitz, Gunter
Timms, Kirsten
Untch, Michael
Elkin, Eric P.
Fasching, Peter A.
Schneeweiss, Andreas
Salat, Christoph
Rezai, Mahdi
Blohmer, Jens Uwe
Zahm, Dirk Michael
Jackisch, Christian
Gerber, Bernd
Klare, Peter
Kuemmel, Sherko
Eidtmann, Holger
Paepke, Stefan
Reid, Julia E.
Nekljudova, Valentina
Hartman, Anne-Renee
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple-negative breast cancer (TNBC).
Krivorotko, Petr
Zhiltsova, Elena
Gigolaeva, Larisa
Emelyanov, Alexander
Pesotskiy, Roman
Yerechshenko, Sergey
Nikolaev, Kirill
Komyahov, Alexander
Ivanova, Olga
Tabagua, Tengiz
Zernov, Konstantin
Ivanov, Vadim
Aseeva, Zalina
Bessonov, Alexander
Semiglazov, Vladimir
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study
Dieci, M. V.
Giorgi, C. A.
Griguolo, G.
Angelini, S.
Miglietta, F.
Giarratano, T.
Falci, C.
Faggioni, G.
Tasca, G.
Mioranza, E.
Vernaci, G.
Menichetti, A.
Mantiero, M.
Genovesi, E.
Frezzini, S.
Saibene, T.
Michieletto, S.
Guarneri, V.
ANNALS OF ONCOLOGY, 2019, 30 : 64 - +
[4] The role of glucocorticoid receptor (GR) expression in predicting pathological complete response (pCR) to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC)
Saha, P.
Turk, A.
Lurain, K.
Baker, G.
Conzen, S.
Nanda, R.
CANCER RESEARCH, 2016, 76
[5] Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC)
Sharma, Priyanka
Stecklein, Shane R.
Kimler, Bruce F.
Khan, Qamar J.
Connor, Carol Sue
McGinness, Marilee
Mammen, Joshua
Wagner, Jamie Lynn
Jensen, Roy A.
Godwin, Andrew K.
Fabian, Carol J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Pathological Complete Response with Platinum Containing Neoadjuvant Chemotherapy in Triple-negative Breast Cancer: An Interventional Study
Jose, Binila mary
Kumar, V. R. Ajith
Meloot, Suma Susan
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2024, 18 (04) : XC1 - XC4
[7] Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC)
Echavarria Diaz-Guardamino, I.
Lopez-Tarruella, S.
Garcia-Saenz, J. A.
Gomez Moreno, H.
Moreno, F.
Jerez, Y.
Fuentes, H.
Marquez-Rodas, I.
Cebollero, M.
Del Monte-Millan, M.
Picornell, A.
Massarrah, T.
Barnadas, A.
Prat, A.
Ballesteros Garcia, A.
Colomer Bosch, R.
Pelaez, B.
Gonzalez-Rivera, M.
Perou, C. M.
Martin, M.
ANNALS OF ONCOLOGY, 2016, 27
[8] Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
Nakashoji, Ayako
Matsui, Akira
Nagayama, Aiko
Iwata, Yuko
Sasahara, Manami
Murata, Yuya
ONCOLOGY LETTERS, 2017, 14 (04) : 4135 - 4141
[9] Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Pohl, E.
Schneeweiss, A.
Hauke, J.
Moebus, V.
Furlanetto, J.
Denkert, C.
Fasching, P. A.
Hanusch, C.
Tesch, H.
Weber-Lassalle, N.
Mueller, V.
Rhiem, K.
Untch, M.
Luebbe, K.
Lederer, B.
Jackisch, C.
Nekljudova, V.
Schmutzler, R. K.
Hahnen, E.
Loibl, S.
ANNALS OF ONCOLOGY, 2018, 29
[10] Thrombocytopenia is associated with pathological complete response to neoadjuvant carboplatin/docetaxel chemotherapy in BRCA wild type triple negative breast cancer
Sharma, Priyanka
Powers, Benjamin C.
Kimler, Bruce F.
Ward, Claire
Klemp, Jennifer R.
Connor, Carol S.
McGinness, Marilee K.
Mammen, Joshua M. V.
Wagner, Jamie L.
Khan, Qamar J.
Jensen, Roy A.
Godwin, Andrew K.
Fabian, Carol J.
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →